Work

Pss13 Cost-effective Analysis of Pegaptanib (macugen®) as Compared With Ranibizumab (lucentis®) for Treating in Age-related Macular Degeneration (amd)

Year: 2008

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/s1098-3015(10)70908-6

Authors: LY Lu, W McGhan

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2052297586

Cites:

Cited by: 1

Related to: 10